CHAMPIONS ONCOLOGY, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CSBR in the last 30 days.
See all $CSBR insider activity →CHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On October 14, 2026, Champions Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting a
Champions Oncology (CSBR) reported a narrowed Q1 loss of $426,000, or $0.03 per share, despite a 62.6% revenue decline to $5.23M. Costs were cut, with R&D spending down significantly. Cash reserves decreased to $4.36M, and working capital stood at $563,000. Management expects current funds to last at least 12 months.
Champions Oncology reported Q1 2027 revenue of $15.23M, up 8.8% YoY, with a net loss of $0.43M. EPS was $(0.03), unchanged from the prior year. Growth was driven by oncology services and data licensing, while commercial and R&D investments increased. Costs of oncology revenue decreased by 5.8%.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CSBR (CHAMPIONS ONCOLOGY, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CSBR coverage spans earnings, financial news and corporate actions.
The filing confirms governance outcomes and shareholder approval of the 2026 equity incentive plan, which can affect future dilution and compensation expectations.
Loss narrowing may support short-term price stability, but revenue drop raises concerns.
Quarterly earnings release with modest revenue growth and flat EPS may influence short‑term price volatility.
Earnings miss with slight revenue growth; cash runway extended to September 2027.
Earnings beat on revenue and margin suggest near‑term upside.
AlphAI scores every news story that mentions CSBR with an AI model for sentiment and relevance, and aggregates insider trades from CHAMPIONS ONCOLOGY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On October 14, 2026, Champions Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting a
3 min readChampions Oncology (CSBR) reported a narrowed Q1 loss of $426,000, or $0.03 per share, despite a 62.6% revenue decline to $5.23M. Costs were cut, with R&D spending down significantly. Cash reserves decreased to $4.36M, and working capital stood at $563,000. Management expects current funds to last at least 12 months.
2 min readChampions Oncology reported Q1 2027 revenue of $15.23M, up 8.8% YoY, with a net loss of $0.43M. EPS was $(0.03), unchanged from the prior year. Growth was driven by oncology services and data licensing, while commercial and R&D investments increased. Costs of oncology revenue decreased by 5.8%.
1 min readChampions Oncology (CSBR) reported Q2 2026 revenue of $15.2M, up 8.8% YoY, with a net loss of $426K. Cash reserves were $4.4M, and management expects funds to last until September 2027. Nine-month revenue rose to $45.6M, but net income turned to a loss of $0.5M. Operating cash flow was negative $2.5M, with $7.1M in cash remaining.
2 min readCHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $15.2 Million Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000 Hackensack, NJ – September 10 , 2026 – Champions Oncology,
2 min readChampions Oncology (CSBR) reported Q1 FY2027 revenue of $15.2M, up 8.8% YoY. Oncology services margin improved to 51% from 43%, and adjusted EBITDA increased to $671K from $59K. The company invested in commercial organization and growth initiatives, with net loss narrowing to $426K from $466K.
2 min readSeveral major companies, including Oracle, Adobe, and Copart, are set to report earnings on Thursday. Estimates for Oracle include EPS of $1.73 and revenue of $19.13B. Other companies reporting include Macy's, Restoration Hardware, and more, covering sectors like software, retail, and automotive services.
2 min readCHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 csbr8-k4302026exhibit991.htm EX-99.1 Document Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Record Annual Revenue of $59 Million Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA Hackensack, NJ – July 27,
4 min readChampions Oncology (NASDAQ:CSBR) recently traded below its 200-day moving average, reaching $5.90, significantly lower than its $6.46 average. Analyst sentiment is bearish, with a "Sell" consensus rating from MarketBeat and a downgrade from Weiss Ratings. Institutional ownership is notable at 41.3%, though mixed, as several funds recently adjusted their positions in the company, which has an $86 million market cap and a negative P/E ratio.
3 min readChampions Oncology, Inc. reported third-quarter fiscal 2026 revenue of $16.6 million, a 2.8% decline year-over-year, largely due to the absence of a $4.5 million data license transaction present in the prior year. The company posted a net loss of $279,000 for the quarter and adjusted EBITDA of $574,000. Despite trading near its 52-week low, InvestingPro analysis suggests the stock is currently overvalued.
2 min read
